CBFA2T3::GLIS2 is NOT classic favorable-risk CBF AML.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I appreciate you sharing your medical context, but I notice your specific question didn't come through in your message. I can see from your recent questions that you're navigating some important treatment decisions around:
- Venetoclax-based regimens for AML
- Post-induction marrow findings (hypocellular marrow and poor morphologic recovery)
- Comparing induction regimens (ADE vs. FLAG-IDA vs. FLAG-IDA with venetoclax)
- CBFA2T3::GLIS2 AML and how it differs from classic favorable-risk CBF AML
These are sophisticated, clinically important questions. Could you please resubmit your specific question? That way I can:
- Provide targeted educational information about the treatment approach you're asking about
- Reference the NCCN Guidelines that apply to your daughter's specific situation
- Help you formulate questions for her oncology team about the findings and options you're considering
- Explain the clinical reasoning behind different treatment choices
Once you share your question, I'll give you a comprehensive, evidence-based response that addresses:
- What the medical evidence shows about these treatment options
- How doctors think about choosing between them
- Specific questions to ask her care team
- What the findings (like hypocellular marrow) typically mean in the treatment context
Please go ahead and ask your specific question, and I'll provide detailed educational information based on current NCCN Guidelines.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ